Preparation and application of metalloproteinase activated CAR-T structure

By introducing TSAR regulatory elements into CAR-T cells, using matrix metalloproteinase in the tumor microenvironment for conditional activation, the problem of off-target effects in CAR-T cell therapy is solved, the safety and efficiency of treatment are improved, and the quality of treatment is ensured. Specific killing of tumor cells.

CN119060196APending Publication Date: 2024-12-03CHENGDU SENYAO LANGYUAN BIOTECHNOLOGY CO LTD
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
CN202310634488.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There are toxic side effects caused by off-target effects in CAR-T cell therapy, leading to normal tissue damage. The existing strategies have limitations and require the development of safer and more efficient immune cell products.

Method used

A conditionally activated chimeric antigen receptor (CAR) is designed, containing TSAR regulatory elements, including serum albumin-binding peptides and matrix metalloproteinase cleavage sequences, and the conditional activation of matrix metalloproteinases that are highly expressed in the tumor microenvironment is reduced. Off-target effect improves safety.

Benefits of technology

Effectively avoid off-target effects, reduce toxic side effects, improve the safety and killing function of engineered immune cells, and ensure specific identification and killing of tumor cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004259532440000191
    Figure BDA0004259532440000191
  • Figure BDA0004259532440000201
    Figure BDA0004259532440000201
  • Figure BDA0004259532440000211
    Figure BDA0004259532440000211
Patent Text Reader

Abstract

The invention provides a preparation method and an application of a metalloproteinase activated CAR-T (Chimeric Antigen Receptor-T) structure. Specifically, the invention provides a conditionally activated chimeric antigen receptor containing a TSAR regulatory element, an engineered immune cell, and a preparation method and application thereof. By utilizing the characteristic of high expression of tumor microenvironment matrix metalloproteinase, the engineered immune cell product based on conditional activation can realize immunotherapy which is not easy to be off target, lower in toxic and side effects and higher in safety.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of genetic engineering and molecular immunology, and in particular to the preparation and application of a metalloproteinase activated CAR-T structure. Background Art

[0002] Tumor cells can evade T cell recognition and attack due to loss / modulation of surface antigens, loss or reduced expression of major histocompatibility complex (MHC) class I molecules, resulting in immune escape. Chimeric antigen receptor T cells, or CAR-T, are a new type of cell therapy product that specifically recognizes and kills tumor cells after genetic engineering. The antigen recognition mediated by CAR-T is not restricted by MHC and has become one of the most promising treatments for malignant tumors. The classic CAR structure includes a tumor-associated antigen binding region, an extracellular hinge region, a transmembrane region, and an intracellular signaling region.

[0003] CAR-T cells targeting CD19 and CD22 have been widely used in the treatment of hematological tumors such as B-cell acute lymphocytic leukemia, chronic lymphocytic leukemia and non-Hodgkin's lymphoma, and have achieved significant therapeutic effects. In recent years, more and more CAR-T cell products have been developed for the treatment of malignant solid tumors, and some have entered the clinical trial stage. Although CAR-T cell therapy has become the most promising biological treatment, the toxic side effects of CAR-T therapy, such as off-target effects of CAR molecules, cytokine release syndrome, and CAR-T-related encephalopathy syndrome, have not yet been resolved. Therefore, while improving the efficacy of CAR-T, it is also crucial to further improve the safety of CAR-T cell products.

[0004] At present, most of the targets of CAR-T cells are tumor-associated antigens rather than tumor-specific antigens, which means that while CAR-T kills tumor cells, it will inevitably kill normal tissue cells expressing the same target antigen (i.e., off-target effect), causing damage or failure of normal tissues and organs, which can be life-threatening in severe cases. There are currently two strategies for off-target effects. One is to select single-chain antibodies with different affinities to the target antigen based on the difference in the amount of surface antigens expressed on normal tissues and organs and malignant tumor cells; the other is to introduce "logic gating" CAR molecules that recognize two or more antigens at the same time or lack specific antigens to optimize CAR's recognition of tumor cells. However, the above two strategies still have limitations.

[0005] Therefore, there is an urgent need in this field to develop a new strategy to target off-target effects and to develop an engineered immune cell product with lower toxic side effects and higher safety. Summary of the invention

[0006] The purpose of the present invention is to provide a conditionally activated chimeric antigen receptor (CAR) and engineered immune cells.

[0007] Another object of the present invention is to provide a preparation method and application of conditionally activated chimeric antigen receptor (CAR) and engineered immune cells.

[0008] Another object of the present invention is to provide an immunotherapy that is less likely to go off-target, has lower toxic side effects, and is safer.

[0009] In a first aspect of the present invention, a conditionally activated chimeric antigen receptor (CAR) is provided, wherein the conditionally activated chimeric antigen receptor comprises:

[0010] (i) an extracellular domain comprising a TSAR regulatory element and an antigen recognition domain;

[0011] (ii) a transmembrane domain linked to the extracellular domain; and

[0012] (iii) an intracellular domain linked to the transmembrane domain;

[0013] in:

[0014] The TSAR regulatory elements include: serum albumin binding peptide and matrix metalloproteinase cleavage sequence;

[0015] The antigen recognition domain targets tumor antigens.

[0016] In another preferred embodiment, the TSAR regulatory element has a nucleotide sequence selected from the following group:

[0017] (a) a nucleotide sequence having 80% or more homology to the sequence shown in SEQ ID NO: 1 (preferably having at least 85%, 90%, 95%, 99% or 100% homology); or

[0018] (b) A nucleotide sequence obtained by adding, deleting, modifying and / or replacing at least one nucleotide based on the sequence shown in SEQ ID NO: 1.

[0019] In another preferred example, the TSAR regulatory element has a nucleotide sequence as shown in SEQ ID NO:1.

[0020] In another preferred embodiment, the TSAR regulatory element has an amino acid sequence selected from the group consisting of:

[0021] (a) an amino acid sequence having 80% or more homology to the sequence shown in SEQ ID NO: 2 (preferably having at least 85%, 90%, 95%, 99% or 100% homology); or

[0022] (b) an amino acid sequence obtained by adding, deleting, modifying and / or substituting at least one amino acid based on the sequence shown in SEQ ID NO: 2.

[0023] In another preferred example, the TSAR regulatory element has an amino acid sequence as shown in SEQ ID NO:2.

[0024] In another preferred embodiment, the serum albumin binding peptide is a human serum albumin binding peptide.

[0025] In another preferred embodiment, the serum albumin binding peptide has a nucleotide sequence selected from the following group:

[0026] (a) a nucleotide sequence having 80% or more homology to the sequence shown in SEQ ID NO: 3 (preferably having at least 85%, 90%, 95%, 99% or 100% homology); or

[0027] (b) A nucleotide sequence obtained by adding, deleting, modifying and / or replacing at least one nucleotide based on the sequence shown in SEQ ID NO: 3.

[0028] In another preferred example, the serum albumin binding peptide has a nucleotide sequence as shown in SEQ ID NO:3.

[0029] In another preferred embodiment, the serum albumin binding peptide has an amino acid sequence selected from the following group:

[0030] (a) an amino acid sequence having 80% or more homology to the sequence shown in SEQ ID NO: 4 (preferably having at least 85%, 90%, 95%, 99% or 100% homology); or

[0031] (b) an amino acid sequence obtained by adding, deleting, modifying and / or substituting at least one amino acid based on the sequence shown in SEQ ID NO: 4.

[0032] In another preferred example, the serum albumin binding peptide has an amino acid sequence as shown in SEQ ID NO:4.

[0033] In another preferred embodiment, the matrix metalloproteinase cleavage sequence is a human matrix metalloproteinase cleavage sequence.

[0034] In another preferred embodiment, the matrix metalloproteinase cleavage sequence has a nucleotide sequence selected from the following group:

[0035] (a) a nucleotide sequence having 80% or more homology to the sequence shown in SEQ ID NO: 5 (preferably having at least 85%, 90%, 95%, 99% or 100% homology); or

[0036] (b) A nucleotide sequence obtained by adding, deleting, modifying and / or replacing at least one nucleotide based on the sequence shown in SEQ ID NO:5.

[0037] In another preferred example, the matrix metalloproteinase cleavage sequence has a nucleotide sequence as shown in SEQ ID NO:5.

[0038] In another preferred embodiment, the matrix metalloproteinase cleavage sequence has an amino acid sequence selected from the group consisting of:

[0039] (a) an amino acid sequence having 80% or more homology to the sequence shown in SEQ ID NO: 6 (preferably having at least 85%, 90%, 95%, 99% or 100% homology); or

[0040] (b) an amino acid sequence obtained by adding, deleting, modifying and / or substituting at least one amino acid based on the sequence shown in SEQ ID NO: 6.

[0041] In another preferred example, the matrix metalloproteinase cleavage sequence has an amino acid sequence as shown in SEQ ID NO:6.

[0042] In another preferred embodiment, the matrix metalloproteinase cleavage sequence is a site recognized and cleaved by matrix metalloproteinase (MMP).

[0043] In another preferred embodiment, the matrix metalloproteinase is selected from the following group: MMP1, MMP2, MMP3, MMP4, MMP5, MMP6, MMP7, MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP18, MMP19, MMP20, MMP21, MMP22, MMP23, MMP24, MMP25, MMP26, or a combination thereof.

[0044] In another preferred embodiment, the matrix metalloproteinase is selected from the following group: MMP1, MMP3, MMP10, MMP12, MMP13, or a combination thereof.

[0045] In another preferred embodiment, the matrix metalloproteinase is MMP1.

[0046] In another preferred embodiment, the conditionally activated chimeric antigen receptor has an amino acid sequence selected from the following group:

[0047] (a) an amino acid sequence having 80% or more homology to the sequence shown in SEQ ID NO: 8 (preferably having at least 85%, 90%, 95%, 99% or 100% homology); or

[0048] (b) an amino acid sequence obtained by adding, deleting, modifying and / or replacing at least one amino acid based on the sequence shown in SEQ ID NO: 8.

[0049] In another preferred embodiment, the conditionally activated chimeric antigen receptor has an amino acid sequence as shown in SEQ ID NO:8.

[0050] In another preferred embodiment, the tumor antigen includes but is not limited to the following group:

[0051] B7-H3, VEGFR-2, CD19, CD20, CD30, CD22, CD25, CD28, CD30, CD33, CD52, CD56, CD80, CD86, CD81, C D123, CD171, CD276, B7H4, CD133, EGFR, GPC3, PMSA, CD3, CEACAM6, c-Met, EGFRvIII, ErbB2, ErbB3 HER-2, HER3, ErbB4 / HER-4, EphA2, IGF1R, GD2, O-acetyl GD2, O-acetyl GD3, GHRHR, GHR, Flt1, KDR, Flt4, CD44V6, CEA, CA125, CD151, CTLA-4, GITR, BTLA, TGFBR2, TGFBR1, IL6R, gp130, Lewis, TNFR1, TNFR2, PD1, PD-L1, PD-L2, HVEM, MAGE-A, mesothel in, NY-ESO-1, PSMA, RANK, RORl, TNFRSF4, CD40, CD137, TWEAK-R, LTPR, LIFRP, LRP5, MUC1, TCRa, TCRp, TLR7, TLR9, PTCH1, WT-1, Robol, Frizzled, OX40, CD79b, Notch-1-4, or combinations thereof.

[0052] In another preferred embodiment, the tumor antigen is B7-H3.

[0053] In another preferred embodiment, the tumor includes but is not limited to the following group:

[0054] Esophageal malignancy, lung malignancy, gastric malignancy, skin malignancy, colorectal malignancy, liver malignancy, pancreatic malignancy, breast malignancy, ovarian malignancy, glioma, head and neck tumor, or a combination thereof.

[0055] In another preferred embodiment, the tumor is an esophageal malignant tumor (esophageal cancer).

[0056] In another preferred embodiment, the tumor is gastric cancer.

[0057] In another preferred embodiment, the tumor is colorectal cancer.

[0058] In another preferred embodiment, the tumor is liver cancer.

[0059] In another preferred embodiment, the tumor is pancreatic cancer.

[0060] In another preferred embodiment, the tumor is melanoma.

[0061] In another preferred embodiment, the tumor is lung cancer.

[0062] In another preferred embodiment, the tumor is ovarian cancer.

[0063] In another preferred embodiment, the tumor is breast cancer.

[0064] In another preferred embodiment, the tumor is a glioma.

[0065] In another preferred embodiment, the tumor is thyroid cancer.

[0066] In another preferred embodiment, the tumor is bladder cancer, prostate cancer, testicular cancer, cervical cancer, endometrial cancer, or skin cancer.

[0067] In another preferred embodiment, the tumor includes diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, brain low-grade glioma, lung squamous cell carcinoma, gastric adenocarcinoma, testicular germ cell tumor, thymoma, uterine carcinosarcoma, or a combination thereof.

[0068] In another preferred embodiment, the conditionally activated chimeric antigen receptor has a structure shown in Formula I:

[0069] SP-TSAR-Binder-H-TM-C-CD3ζ(I)

[0070] In the formula,

[0071] SP is none or signal peptide sequence;

[0072] TSAR is the TSAR regulatory element;

[0073] Binder is an antigen recognition domain that specifically binds to tumor antigens;

[0074] H is no or hinge region;

[0075] TM is the transmembrane domain;

[0076] C is the co-stimulatory signaling domain;

[0077] CD3ζ is a cytoplasmic signaling sequence derived from CD3ζ (including wild type or mutant / modified form thereof);

[0078] The "-" is a connecting peptide or a peptide bond.

[0079] In another preferred embodiment, the SP is selected from the signal peptides of the following histones: CD8, GM-CSF, CD4, CD28, CD137, or mutants / modified forms thereof, or a combination thereof.

[0080] In another preferred embodiment, the Binder is a B7-H3 single-chain antibody (B7-H3 scFv).

[0081] In another preferred embodiment, the H is selected from the hinge region of the following histones: CD8, CD28, CD137, IgG, or a combination thereof.

[0082] In another preferred embodiment, the H is the CD8 hinge region.

[0083] In another preferred embodiment, the TM is selected from the transmembrane region of the following group of proteins: CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, CD278, CD152, CD279, CD233, or their mutants / modified forms, or their combinations.

[0084] In another preferred embodiment, the TM is the CD8 transmembrane region.

[0085] In another preferred embodiment, the C is selected from the co-stimulatory signal domain of the following group of proteins: OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD70, CD134, 4-1BB (CD137), PD-1, Dap10, LIGHT, NKG2C, B7-H3, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), NKG2D, GITR, OX40L, 2B4, TLR, or its mutant / modified form, or a combination thereof.

[0086] In another preferred embodiment, the C is a CD137 (4-1BB) co-stimulatory signaling domain, a CD28 co-stimulatory signaling domain, or a combination thereof.

[0087] In the second aspect of the present invention, a nucleic acid molecule is provided, wherein the nucleic acid molecule encodes the conditionally activated chimeric antigen receptor as described in the first aspect of the present invention.

[0088] In another preferred embodiment, the nucleic acid molecule has a nucleotide sequence selected from the following group:

[0089] (a) a nucleotide sequence having 80% or more homology to the sequence shown in SEQ ID NO:7 (preferably having at least 85%, 90%, 95%, 99% or 100% homology); or

[0090] (b) A nucleotide sequence obtained by adding, deleting, modifying and / or replacing at least one nucleotide based on the sequence shown in SEQ ID NO:7.

[0091] In another preferred example, the nucleic acid molecule has a nucleotide sequence as shown in SEQ ID NO:7.

[0092] In the third aspect of the present invention, a vector is provided, wherein the vector contains the nucleic acid molecule as described in the second aspect of the present invention.

[0093] In another preferred embodiment, the vector is selected from the group consisting of DNA, RNA, plasmid, lentiviral vector, adenoviral vector, retroviral vector, transposon, or a combination thereof.

[0094] In another preferred embodiment, the vector is a lentiviral vector.

[0095] In another preferred embodiment, the vector is selected from the following group: pTomo lentiviral vector, plenti, pLVTH, pLJM1, pHCMV, pLBS.CAG, pHR, pLV, etc.

[0096] In another preferred embodiment, the vector further includes a member selected from the following group: a promoter, a transcription enhancing element WPRE, a long terminal repeat sequence LTR, etc.

[0097] In the fourth aspect of the present invention, a host cell is provided, wherein the host cell contains the vector as described in the third aspect of the present invention, or an exogenous nucleic acid molecule as described in the second aspect of the present invention is integrated into its chromosome, or the host cell expresses the conditionally activated chimeric antigen receptor as described in the first aspect of the present invention.

[0098] In the fifth aspect of the present invention, an engineered immune cell is provided, wherein the engineered immune cell contains the vector as described in the third aspect of the present invention, or an exogenous nucleic acid molecule as described in the second aspect of the present invention is integrated into its chromosome, or it expresses the conditionally activated chimeric antigen receptor as described in the first aspect of the present invention, and the engineered immune cell is a T cell, a NK cell, a NKT cell, or a macrophage.

[0099] In another preferred embodiment, the engineered immune cells include autologous or allogeneic αβT cells, γδT cells, NKT cells, NK cells, or a combination thereof.

[0100] In another preferred embodiment, the engineered immune cells are CAR-T cells or CAR-NK cells.

[0101] In the sixth aspect of the present invention, a method for preparing the engineered immune cells as described in the fifth aspect of the present invention is provided, the method comprising the following steps: transducing the nucleic acid molecule as described in the second aspect of the present invention or the vector as described in the third aspect of the present invention into the immune cells, thereby obtaining the engineered immune cells.

[0102] In another preferred embodiment, the method further comprises the step of testing the function and effectiveness of the obtained engineered immune cells.

[0103] In a seventh aspect of the present invention, a pharmaceutical composition is provided, comprising:

[0104] (Z1) the conditionally activated chimeric antigen receptor as described in the first aspect of the present invention, the nucleic acid molecule as described in the second aspect of the present invention, the vector as described in the third aspect of the present invention, the host cell as described in the fourth aspect of the present invention, the engineered immune cell as described in the fifth aspect of the present invention, or a combination thereof; and

[0105] (Z2) a pharmaceutically acceptable carrier, diluent or excipient.

[0106] In another preferred embodiment, the pharmaceutical composition is a liquid preparation.

[0107] In another preferred embodiment, the pharmaceutical composition is in the form of an injection.

[0108] In another preferred embodiment, the concentration of the engineered immune cells in the pharmaceutical composition is 1×10 3 -1×10 8 cells / ml, preferably 1×10 4 -1×10 7 cells / ml.

[0109] In the eighth aspect of the present invention, there is provided a use of the conditionally activated chimeric antigen receptor as described in the first aspect of the present invention, the nucleic acid molecule as described in the second aspect of the present invention, the vector as described in the third aspect of the present invention, the host cell as described in the fourth aspect of the present invention, and / or the engineered immune cell as described in the fifth aspect of the present invention for preparing a drug or preparation for preventing and / or treating cancer or tumors.

[0110] In another preferred embodiment, the tumor is a tumor that highly expresses matrix metalloproteinases.

[0111] In another preferred embodiment, the tumor includes but is not limited to the following group:

[0112] Esophageal malignancy, lung malignancy, gastric malignancy, skin malignancy, colorectal malignancy, liver malignancy, pancreatic malignancy, breast malignancy, ovarian malignancy, glioma, head and neck tumor, or a combination thereof.

[0113] In another preferred embodiment, the tumor is an esophageal malignant tumor (esophageal cancer).

[0114] In another preferred embodiment, the tumor is gastric cancer.

[0115] In another preferred embodiment, the tumor is colorectal cancer.

[0116] In another preferred embodiment, the tumor is liver cancer.

[0117] In another preferred embodiment, the tumor is pancreatic cancer.

[0118] In another preferred embodiment, the tumor is melanoma.

[0119] In another preferred embodiment, the tumor is lung cancer.

[0120] In another preferred embodiment, the tumor is ovarian cancer.

[0121] In another preferred embodiment, the tumor is breast cancer.

[0122] In another preferred embodiment, the tumor is a glioma.

[0123] In another preferred embodiment, the tumor is thyroid cancer.

[0124] In another preferred embodiment, the tumor is bladder cancer, prostate cancer, testicular cancer, cervical cancer, endometrial cancer, or skin cancer.

[0125] In another preferred embodiment, the tumor includes diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, brain low-grade glioma, lung squamous cell carcinoma, gastric adenocarcinoma, testicular germ cell tumor, thymoma, uterine carcinosarcoma, or a combination thereof.

[0126] In the ninth aspect of the present invention, there is provided a use of the engineered immune cell as described in the fifth aspect of the present invention, or the pharmaceutical composition as described in the seventh aspect of the present invention, for preventing and / or treating cancer or tumors.

[0127] In a tenth aspect of the present invention, a method for modifying a chimeric antigen receptor (CAR) is provided, the method comprising the steps of:

[0128] (a) providing a chimeric antigen receptor to be engineered; and

[0129] (b) Introducing a TSAR regulatory element in front of the antigen recognition domain of the chimeric antigen receptor to be modified, thereby obtaining a conditionally activated chimeric antigen receptor with higher safety.

[0130] In the eleventh aspect of the present invention, a kit for preparing the engineered immune cells as described in the fifth aspect of the present invention is provided, the kit comprising a container, and a nucleic acid molecule as described in the second aspect of the present invention, or a vector as described in the third aspect of the present invention, located in the container.

[0131] In the twelfth aspect of the present invention, a method for treating cancer or tumors is provided, comprising administering an effective amount of the engineered immune cells as described in the fifth aspect of the present invention, or the pharmaceutical composition as described in the seventh aspect of the present invention to a subject in need of treatment.

[0132] In another preferred embodiment, the engineered immune cells or CAR immune cells contained in the pharmaceutical composition are cells derived from the subject (autologous cells).

[0133] In another preferred embodiment, the engineered immune cells or CAR immune cells contained in the pharmaceutical composition are cells derived from healthy individuals (allogeneic cells).

[0134] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0135] Figure 1 A schematic diagram of the TSAR.CAR molecular structure is shown.

[0136] Figure 2 A diagram of the TSAR.CAR antitumor pattern is shown.

[0137] Figure 3 Flow cytometric analysis of B7-H3 expression levels on the surface of malignant esophageal tumor cell lines is shown.

[0138] Figure 4 Western Blot analysis of B7-H3 expression in malignant esophageal tumor cell lines is shown.

[0139] Figure 5 Protein database analysis of B7-H3 protein expression levels in different tissues is shown.

[0140] Figure 6 The GEPIA database analysis of B7-H3 RNA expression levels in different tumor tissues is shown.

[0141] Figure 7 Protein database analysis of B7-H3 protein expression levels in different tumor tissues (HPA00928 antibody) is shown.

[0142] Figure 8 The RNA expression levels of different MMPs in 120 pairs of ESCC tissues are shown.

[0143] Fig. 9 Shown is the expression of MMP1 and MMP11 detected by Western blot in 10 esophageal squamous cell carcinoma cell lines.

[0144] Fig.10 Western blot detection of KYSE150, KYSE150-hMMP1 full length, and KYSE150-hMMP1activated length expression levels is shown.

[0145] Fig.11 Flow cytometric analysis of HSA binding to HSABP is shown.

[0146] Fig.12 Flow cytometric analysis of cleavage of B7-H3.TSAR molecules by MMP1 treatment is shown.

[0147] Fig.13 The in vitro cell experiment analysis shows the difference in the killing ability of B7-H3.TSAR.CAR-T and B7-H3.CAR-T against KYSE150 and KYSE150 overexpressing human MMP1.

[0148] Fig.14 In vivo animal experiments were shown to compare the killing abilities of B7-H3.TSAR.CAR-T and B7-H3.CAR-T.

[0149] Fig.15 In vitro experimental analysis shows the anti-tumor activity of B7-H3.TSAR.CAR-T against colon cancer, liver cancer, gastric cancer, pancreatic cancer, lung cancer, melanoma, ovarian cancer, and breast cancer cell lines. DETAILED DESCRIPTION

[0150] After extensive and in-depth research and a large amount of screening, the inventors unexpectedly discovered for the first time a special molecular structure that can increase the safety of engineered immune cells (such as chimeric antigen receptor T cells, CAR-T cells) in treating malignant solid tumors: TSAR.CAR (Tumour-Selectively Activating Reaction CAR). That is, a conditionally activated regulatory element (TSAR regulatory element) is inserted after the 5'-end signal peptide of the traditional classic CAR molecular structure and before the antigen recognition domain, which includes: human serum albumin binding peptide (HSABP) and human matrix metalloproteinase (MMP) cleavage sequence (MMPCS). The CAR and engineered immune cells of the present invention utilize the characteristics of high expression of matrix metalloproteinases in the tumor microenvironment to achieve conditional activation based on matrix metalloproteinases, thereby reducing the toxic and side effects caused by off-target effects during immunotherapy, and improving the safety of engineered immune cell products. The present invention was completed on this basis.

[0151] the term

[0152] In order that the present disclosure may be more readily understood, certain terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms shall have the meaning given below.

[0153] The term "about" can refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined.

[0154] The term "administering" refers to the physical introduction of the product of the invention into a subject using any of a variety of methods and delivery systems known to those skilled in the art, including intravenous, intratumoral, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, such as by injection or infusion.

[0155] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".

[0156] "Transduction", "transfection", "transformation" or other terms used herein refer to the process of transferring exogenous polynucleotides into host cells, transcribing and translating them to produce polypeptide products, including the use of plasmid molecules to introduce exogenous polynucleotides into host cells.

[0157] "Gene expression" or "expression" refers to the process of gene transcription, translation and post-translational modification to produce the RNA or protein product of the gene.

[0158] Conservative amino acid substitutions are known in the art. In some embodiments, the potential substituted amino acids are within one or more of the following groups: glycine, alanine; and valine, isoleucine, leucine and proline; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine lysine, arginine and histidine; and / or phenylalanine, tryptophan and tyrosine; methionine and cysteine. In addition, the present invention also provides non-conservative amino acid substitutions that allow amino acid substitutions from different groups.

[0159] It should be understood that for any method described herein comprising more than one step, the order of the steps is not necessarily limited to the order described in the examples.

[0160] Conventional strategies for off-target effects

[0161] (1) According to the difference in the amount of surface antigen expression between normal tissues and organs and malignant tumor cells, single-chain antibodies with different affinities to the target antigen are selected. Compared with normal tissues and organs, malignant tumor cells that express relatively high levels of target antigens can be killed by CAR-T cells expressing low-affinity scFv, thus forming a situation where only tumor cells with high density of target antigens can provide sufficient interaction to activate CAR-T cells. Studies have shown that CAR-T cells with low affinity for CD19 molecules can not only effectively kill tumor cells, but also have stronger proliferation ability and low side effects. However, there are still great challenges in finding and identifying highly effective CAR low-affinity single-chain antibodies, and some studies have found that in malignant solid tumors, recombinant CAR-T cells expressing low-affinity single-chain antibodies have significantly lower anti-tumor activity than CAR-T cells expressing high-affinity single-chain antibodies.

[0162] (2) Introducing "logic gating" CAR molecules that recognize two or more antigens or lack specific antigens at the same time to optimize CAR's recognition of tumor cells. For example, the synNotch system first recognizes the first target antigen through a synthetic Notch receptor, and after activation, it can induce the expression of CAR molecules targeting the second target antigen. The dual-receptor CAR molecule recognizes two target antigens on the cell surface at the same time to activate CAR-T cells. Some researchers have also found that by connecting CD3ζ and the costimulatory domain to two receptors respectively, such as one receptor with a CD3ζ activation domain and the other receptor with a costimulatory domain, when both receptors bind to the corresponding target antigens, the activation of the entire CAR-T cell can be completed and the killing function can be performed. Recently, scientists have developed an inhibitory CAR molecule that connects the receptor that recognizes non-malignant tumor cells with the co-inhibitory domain to ensure that the activated CAR-T only kills tumor cells. However, this sequential activation method of "logic gating" will delay the time from CAR-T cells being infused into the body to taking effect, and the cytokines produced by the reaction are also uncontrollable.

[0163] The CAR and engineered immune cells of the present invention utilize the high expression of matrix metalloproteinases in the tumor microenvironment to achieve conditional activation based on metalloproteinases, thereby reducing toxic and side effects caused by off-target effects during immunotherapy and improving the safety of engineered immune cell products.

[0164] TSAR regulatory elements

[0165] As mentioned above, the conditionally activated CAR molecule of the present invention contains a TSAR (tumor-selectively activating reaction) regulatory element. Typically, the TSAR regulatory element of the present invention has a nucleotide sequence as shown in SEQ ID NO: 1 and an amino acid sequence as shown in SEQ ID NO: 2.

[0166] The TSAR regulatory element consists of two parts: a serum albumin binding peptide and a matrix metalloproteinase cleavage sequence. Typically, the serum albumin binding peptide of the present invention is a human serum albumin binding peptide (human serum albumin binding peptide, HSABP); the matrix metalloproteinase cleavage sequence (matrixmetalloproteinase cleavage sequence, MMPCS) of the present invention is a human matrix metalloproteinase cleavage sequence.

[0167] The serum albumin binding peptide can bind to serum albumin (e.g., human serum albumin (HSA)), and interfere with the binding of the single-chain antibody of the CAR molecule to the tumor cell surface antigen through steric hindrance, so that the genetically engineered cells such as CAR-T cells are in a low / inactivated state. The serum albumin binding peptide of the present invention preferably has a nucleotide sequence as shown in SEQ ID NO: 3 and an amino acid sequence as shown in SEQ ID NO: 4.

[0168] The matrix metalloproteinase cleavage sequence can be specifically cleaved by matrix metalloproteinases (MMPs), thereby relieving the steric hindrance effect mediated by HSABP and activating genetically engineered cells such as CAR-T cells. The matrix metalloproteinase cleavage sequence of the present invention preferably has a nucleotide sequence as shown in SEQ ID NO: 5 and an amino acid sequence as shown in SEQ ID NO: 6.

[0169] Matrix metalloproteinases (MMPs) and matrix metalloproteinase cleavage sequences (MMPCS)

[0170] The tumor microenvironment (TME) is the internal environment in which tumor cells grow, and it is also an important reason for the poor effect of CAR-T cells in treating malignant solid tumors. The tumor microenvironment is mainly composed of tumor cells and their surrounding immune cells, inflammatory cells, nearby interstitial tissues, blood vessels, and various cytokines, chemokines, and metalloproteinases (MMPs).

[0171] MMPs are a family of zinc- and calcium-dependent proteases that can degrade the extracellular matrix and basement membrane to promote the invasion and metastasis of tumor cells. Studies have found that MMPs are widely present in the tumor microenvironment of lung cancer, breast cancer, ovarian cancer, cervical cancer, liver cancer, rectal cancer, bladder cancer, etc., and their increased expression is closely related to the poor prognosis of patients. Esophageal malignant tumor tissues highly express MMP1, MMP3, MMP10, MMP12, and MMP13. Among them, the high expression of MMP1 can not only promote tumor cell proliferation, but also has a direct relationship with the poor effect of neoadjuvant chemotherapy. Patients with malignant esophageal cancer with high expression of MMP1 have a poor prognosis.

[0172] The matrix metalloproteinase cleavage sequence (MMPCS) is a site specifically recognized and cleaved by matrix metalloproteinases, which can relieve the steric hindrance effect mediated by HSABP and activate genetically engineered cells such as CAR-T cells. The matrix metalloproteinase cleavage sequence of the present invention preferably has a nucleotide sequence as shown in SEQ ID NO: 5 and an amino acid sequence as shown in SEQ ID NO: 6.

[0173] CAR of the present invention (TSAR.CAR)

[0174] Chimeric antigen receptor (CAR) is composed of an extracellular antigen recognition region, a transmembrane region, and an intracellular co-stimulatory signal region.

[0175] The design of CAR has gone through the following process: The first generation of CAR has only one intracellular signal component CD3ζ or FcγRI molecule. Since there is only one activation domain in the cell, it can only cause short-term T cell proliferation and less cytokine secretion, but cannot provide long-term T cell proliferation signals and sustained anti-tumor effects in vivo, so it has not achieved good clinical efficacy. The second generation of CAR introduces a co-stimulatory molecule such as CD28, 4-1BB, OX40, and ICOS based on the original structure. Compared with the first generation of CAR, the function is greatly improved, further enhancing the persistence of CAR-T cells and the ability to kill tumor cells. On the basis of the second generation of CAR, some new immune co-stimulatory molecules such as CD27 and CD134 are connected in series, and developed into the third and fourth generation of CAR.

[0176] The extracellular segment of CAR can recognize a specific antigen, and then transduce the signal through the intracellular domain, causing cell activation and proliferation, cytolytic toxicity and secretion of cytokines, thereby eliminating target cells. First, the patient's autologous cells (or allogeneic donors) are separated, activated and genetically modified to produce CAR immune cells, and then injected into the same patient. This method has a very low probability of graft-versus-host disease, and the antigen is recognized by immune cells in a non-MHC restricted manner.

[0177] CAR-immune cell therapy has achieved a very high clinical response rate in the treatment of hematological malignancies. This high response rate cannot be achieved by any previous treatment method and has triggered a wave of clinical research around the world.

[0178] Specifically, the chimeric antigen receptor of the present invention includes an extracellular domain, a transmembrane domain, and an intracellular domain.

[0179] The extracellular domain includes a target-specific binding element. The extracellular domain can be an scFv of an antibody based on antigen-antibody specific binding, or a natural sequence or a derivative thereof based on ligand-receptor specific binding.

[0180] The intracellular domain includes a co-stimulatory signaling region and a zeta chain portion. The co-stimulatory signaling region refers to a portion of the intracellular domain that includes co-stimulatory molecules. Co-stimulatory molecules are cell surface molecules required for the effective response of lymphocytes to antigens, rather than antigen receptors or their ligands.

[0181] Between the extracellular domain and the transmembrane domain of CAR, or between the cytoplasmic domain and the transmembrane domain of CAR, a joint may be incorporated. As used herein, the term "joint" generally refers to any oligopeptide or polypeptide that acts to connect the transmembrane domain to the extracellular domain or cytoplasmic domain of a polypeptide chain. The joint may include 0-300 amino acids, preferably 2 to 100 amino acids and most preferably 3 to 50 amino acids.

[0182] The CAR of the present invention, when expressed in T cells, can recognize antigens based on antigen binding specificity. When it binds to its associated antigen, it affects tumor cells, causing them to not grow, be caused to die or otherwise be affected, and causes the patient's tumor load to shrink or be eliminated. The antigen binding domain is preferably fused with one or more intracellular domains from a costimulatory molecule and a ζ chain.

[0183] Typically, the CAR of the present invention has the structure shown in Formula I:

[0184] SP-TSAR-Binder-H-TM-C-CD3ζ(I)

[0185] wherein each term is as defined above.

[0186] It should be understood that the CAR of the present invention can be applied to a variety of tumor antigens and a variety of tumor types. When different Binders are selected, the CAR of the present invention can target the tumor antigens and tumor cells that the Binder specifically binds to accordingly.

[0187] Taking esophageal malignant tumors and B7-H3 targets as an example (ie, when the Binder is a B7-H3 single-chain antibody (B7-H3scFv)), preferably, the CAR of the present invention has a nucleotide sequence as shown in SEQ ID NO: 7 and an amino acid sequence as shown in SEQ ID NO: 8.

[0188] In non-tumor areas, HSABP in the TSAR regulatory element binds to the highly abundant HSA in the body, and masks the binding of B7-H3 scFv to the antigen through the steric hindrance effect, so that CAR-T is in a low / unactivated state, with weak or no killing function, which can effectively avoid off-target effects. When the TSAR.CAR-T molecule enters the tumor tissue, a large number of matrix metalloproteinases (such as MMP1) in the malignant tumor tissue recognize the MMPCS in the TSAR regulatory element, remove the HSABP at the front end of the B7-H3 scFv and its bound HSA, and relieve the steric hindrance effect mediated by HSABP, so that B7-H3 scFv can smoothly and efficiently bind to the target antigen on the surface of the tumor cell, transforming into an activated CAR-T cell, and exerting the killing function of specific tumor cells. Therefore, based on the design of the TSAR regulatory element, conditional activation mediated by matrix metalloproteinases is achieved, and the safety of CAR products is improved.

[0189] Engineered immune cells of the present invention

[0190] The chimeric antigen receptor immune cell of the present invention can be a T cell, a NK cell, a NKT cell, or a macrophage.

[0191] CAR-T cells have the following advantages over other T-cell-based treatments: (1) The action process of CAR-T cells is not restricted by MHC; (2) Since many tumor cells express the same tumor markers, once the CAR gene construction targeting a certain tumor marker is completed, it can be widely used; (3) CAR can use both tumor protein markers and glycolipid non-protein markers, expanding the target range of tumor markers; (4) The use of the patient's own cells reduces the risk of rejection; (5) CAR-T cells have immune memory function and can survive in the body for a long time.

[0192] Natural killer (NK) cells are a major type of immune effector cells that protect the body from viral infection and tumor cell invasion through non-antigen specific pathways. Engineered (genetically modified) NK cells may acquire new functions, including the ability to specifically recognize tumor antigens and have enhanced anti-tumor cytotoxic effects.

[0193] Compared with autologous CAR-T cells, CAR-NK cells also have the following advantages, such as: (1) they directly kill tumor cells by releasing perforin and granzyme, but have no killing effect on normal cells in the body; (2) they release very small amounts of cytokines, thereby reducing the risk of cytokine storms; (3) they are very easy to expand in vitro and develop into "ready-made" products. Other than that, it is similar to CAR-T cell therapy.

[0194] Carrier

[0195] The nucleic acid sequence encoding the desired molecule can be obtained using recombinant methods known in the art, such as, for example, by screening a library from a cell expressing the gene, by obtaining the gene from a known vector comprising the gene, or by directly isolating from cells and tissues comprising the gene using standard techniques. Alternatively, the gene of interest can be produced synthetically.

[0196] The present invention also provides vectors comprising nucleic acid molecules of the present invention. Vectors derived from retroviruses such as lentiviruses are suitable tools for achieving long-term gene transfer because they allow long-term, stable integration of transgenes and their proliferation in daughter cells. Lentiviral vectors have advantages over vectors derived from oncogenic retroviruses such as murine leukemia viruses because they can transduce non-proliferating cells, such as hepatocytes. They also have the advantage of low immunogenicity.

[0197] In brief summary, the expression cassette or nucleic acid sequence of the present invention is usually operably connected to a promoter and incorporated into an expression vector. The vector is suitable for replication and integration into eukaryotic cells. Typical cloning vectors contain transcription and translation terminators, initiation sequences, and promoters that can be used to regulate the expression of the desired nucleic acid sequence.

[0198] The expression constructs of the present invention can also be used for nucleic acid immunization and gene therapy using standard gene delivery protocols. Methods of gene delivery are known in the art. See, for example, U.S. Patent Nos. 5,399,346, 5,580,859, 5,589,466, which are incorporated herein by reference in their entirety. In another embodiment, the present invention provides a gene therapy vector.

[0199] The nucleic acid can be cloned into many types of vectors. For example, the nucleic acid can be cloned into such vectors, which include but are not limited to plasmids, phagemids, phage derivatives, animal viruses and cosmids. Specific vectors of interest include expression vectors, replication vectors, probe generation vectors and sequencing vectors.

[0200] Further, expression vector can be provided to cell in the form of viral vector. Viral vector technology is well known in the art and is described in, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York) and other virology and molecular biology manuals. Viruses that can be used as vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, herpes viruses and slow viruses. Generally, suitable vectors are included in at least one organism that works on the origin of replication, promoter sequence, convenient restriction enzyme sites and one or more selectable markers (for example, WO01 / 96584; WO01 / 29058; and U.S. Patent number 6,326,193).

[0201] Many virus-based systems have been developed for transferring genes into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. The selected gene can be inserted into a vector and packaged into retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to a subject's cells in vivo or in vitro. Many retroviral systems are known in the art. In some embodiments, adenoviral vectors are used. Many adenoviral vectors are known in the art. In one embodiment, a lentiviral vector is used.

[0202] Additional promoter elements, such as enhancers, can regulate the frequency of transcription initiation. Typically, these are located in the 30-110 bp region upstream of the start site, although recently it has been shown that many promoters also contain functional elements downstream of the start site. The spacing between promoter elements is often flexible so that when an element is inverted or moved relative to another, the promoter function is maintained. In the thymidine kinase (tk) promoter, the spacing between promoter elements can be increased to 50 bp apart before activity begins to decline. Depending on the promoter, it is shown that individual elements can work cooperatively or independently to start transcription.

[0203] An example of a suitable promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that can drive any polynucleotide sequence operably connected thereto to express at a high level. Another example of a suitable promoter is elongation growth factor-1α (EF-1α). However, other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr (Epstein-Barr) virus immediate early promoter, Rous sarcoma virus promoter, and human gene promoters, such as but not limited to actin promoter, myosin promoter, heme promoter, and creatine kinase promoter. Further, the present invention should not be limited to the application of constitutive promoters. Inducible promoters are also considered to be part of the present invention. The use of an inducible promoter provides a molecular switch that can turn on the expression of a polynucleotide sequence operably linked to an inducible promoter when such expression is desired, or turn off expression when expression is undesirable. Examples of inducible promoters include, but are not limited to, metallothionein promoters, glucocorticoid promoters, progesterone promoters, and tetracycline promoters.

[0204] In order to evaluate the expression of CAR polypeptides or parts thereof, the expression vector introduced into the cell may also include any one or both of a selectable marker gene or a reporter gene to facilitate identification and selection of expressing cells from a cell population seeking to be transfected or infected by a viral vector. In other aspects, selectable markers may be carried on a single DNA segment and used for co-transfection procedures. Both selectable markers and reporter genes may be flanked by appropriate regulatory sequences so that they can be expressed in host cells. Useful selectable markers include, for example, antibiotic resistance genes, such as neo and the like.

[0205] Reporter gene is used to identify the cell of potential transfection and to evaluate the functionality of regulatory sequence.Usually, reporter gene is following gene: it is not present in receptor organism or tissue or is expressed by receptor organism or tissue, and its coded polypeptide, the expression of this polypeptide is clearly represented by some easily detectable properties such as enzymatic activity.After DNA has been introduced into receptor cell, the expression of reporter gene is measured under suitable time.Suitable reporter gene can comprise the gene of coding luciferase, beta-galactosidase, chloramphenicol acetyltransferase, secretory alkaline phosphatase or green fluorescent protein (for example, Ui-Tei etc., 2000FEBS Letters479:79-82).

[0206] Suitable expression systems are well known and can be prepared using known techniques or obtained commercially. Typically, constructs with a minimum of 5 flanking regions that show the highest level of reporter gene expression are identified as promoters. Such promoter regions can be linked to reporter genes and used to evaluate the ability of agents to regulate promoter-driven transcription.

[0207] Methods for introducing genes into cells and expressing genes into cells are known in the art. In the context of expression vectors, vectors can be easily introduced into host cells, such as mammalian, bacterial, yeast or insect cells, by any method known in the art. For example, expression vectors can be transferred into host cells by physical, chemical or biological means.

[0208] Physical methods for introducing polynucleotides into host cells include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like. Methods for producing cells containing vectors and / or exogenous nucleic acids are well known in the art. See, for example, Sambrook et al. (2001, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York). A preferred method for introducing polynucleotides into host cells is calcium phosphate transfection.

[0209] Biological methods for introducing polynucleotides of interest into host cells include the use of DNA and RNA vectors. Viral vectors, particularly retroviral vectors, have become the most widely used methods for inserting genes into mammalian cells such as human cells. Other viral vectors can be derived from lentiviruses, poxviruses, herpes simplex virus I, adenoviruses, and adeno-associated viruses, etc. See, for example, U.S. Patent Nos. 5,350,674 and 5,585,362.

[0210] Chemical means for introducing polynucleotides into host cells include colloidal dispersion systems, such as macromolecular complexes, nanocapsules, microspheres, beads; and lipid-based systems, including oil-in-water emulsions, micelles, mixed micelles and liposomes. An exemplary colloidal system used as a delivery vehicle in vitro and in vivo is a liposome (e.g., an artificial membrane vesicle).

[0211] In the case of using a non-viral delivery system, an exemplary delivery vehicle is a liposome. Consider using lipid preparations to introduce nucleic acid into a host cell (in vitro, ex vivo or in vivo). On the other hand, the nucleic acid can be associated with a lipid. Nucleic acids associated with lipids can be encapsulated in the aqueous interior of the liposome, dispersed in the lipid bilayer of the liposome, attached to the liposome through a connecting molecule associated with both the liposome and the oligonucleotide, trapped in the liposome, compounded with the liposome, dispersed in a solution comprising lipids, mixed with lipids, combined with lipids, included in lipids as a suspension, included in micelles or compounded with micelles, or otherwise associated with lipids. The lipids, lipid / DNA or lipid / expression vectors associated with the composition are not limited to any specific structure in the solution. For example, they can be present in a bilayer structure, as micelles or have a "collapsed (collapsed)" structure. They can also be simply dispersed in a solution, possibly forming aggregates of size or shape inhomogeneity. Lipid is a fatty substance, which can be a naturally occurring or synthetic lipid. For example, lipids include fat droplets that occur naturally in the cytoplasm as well as compounds that contain long-chain aliphatic hydrocarbons and their derivatives such as fatty acids, alcohols, amines, amino alcohols, and aldehydes.

[0212] In a preferred embodiment of the present invention, the vector is a lentiviral vector.

[0213] Pharmaceutical composition

[0214] The present invention provides a pharmaceutical composition, which contains: a conditionally activated chimeric antigen receptor as described in the first aspect of the present invention, a nucleic acid molecule as described in the second aspect of the present invention, a vector as described in the third aspect of the present invention, a host cell as described in the fourth aspect of the present invention, or an engineered immune cell as described in the fifth aspect of the present invention, and a pharmaceutically acceptable carrier, diluent or excipient. In one embodiment, the pharmaceutical composition is a liquid preparation. Preferably, the pharmaceutical composition is an injection. Preferably, the concentration of the engineered immune cells in the pharmaceutical composition is 1×10 3 -1×10 8 cells / ml, preferably 1×10 4 -1×10 7 cells / ml.

[0215] In one embodiment, the formulation may include a buffer such as neutral buffered saline, sulfate buffered saline, etc.; a carbohydrate such as glucose, mannose, sucrose or dextran, mannitol; a protein; a polypeptide or an amino acid such as glycine; an antioxidant; a chelating agent such as EDTA or glutathione; an adjuvant (e.g., aluminum hydroxide); and a preservative. The pharmaceutical composition of the present invention is preferably formulated for intravenous administration.

[0216] Therapeutic applications

[0217] In one embodiment, the present invention includes a type of cell therapy that separates the patient's autologous T cells (or allogeneic donors), activates and genetically modifies them to produce CAR-T cells, which are then injected into the same patient. This approach makes the probability of graft-versus-host reaction extremely low, and the antigen is recognized by the T cell in an MHC-free manner. In addition, one CAR-T can treat all cancers that express the antigen. Unlike antibody therapy, CAR-T cells can replicate in vivo, producing long-term persistence that can lead to sustained tumor control.

[0218] The CAR-T cells of the present invention may be administered alone or as a pharmaceutical composition in combination with a diluent and / or with other components such as IL-2, IL-17 or other cytokines or cell populations. In short, the pharmaceutical composition of the present invention may include a target cell population as described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.

[0219] The pharmaceutical composition and engineered immune cells of the present invention can be administered in a manner suitable for the disease to be treated (or prevented). The quantity and frequency of administration will be determined by factors such as the patient's condition, and the type and severity of the patient's disease, or can be determined by clinical trials.

[0220] When an "immunologically effective amount", "anti-tumor effective amount", "tumor-suppressive effective amount" or "therapeutic amount" is indicated, the exact amount of the composition of the present invention to be administered can be determined by a physician, taking into account individual differences in the patient's (subject's) age, weight, tumor size, degree of infection or metastasis, and condition. The pharmaceutical composition comprising the T cells described herein can be administered in an amount of 10 4 Up to 10 9 The dosage is preferably 10 cells / kg body weight. 5 Up to 10 7 The T cell composition can also be administered multiple times at these doses. The cells can be administered using well-known infusion techniques in immunotherapy (see, e.g., Rosenberg et al., New Eng. J. of Med. 319:1676, 1988). The optimal dose and treatment regimen for a specific patient can be easily determined by a medical technician by monitoring the patient's disease signs and adjusting the treatment accordingly.

[0221] Administration of the subject composition can be carried out in any convenient manner, including by spraying, injection, swallowing, infusion, implantation or transplantation. The compositions described herein can be administered to the patient subcutaneously, intradermally, intratumorally, intranodally, intraspinal, intramuscularly, by intravenous injection or intraperitoneally. In one embodiment, the T cell composition of the present invention is administered to the patient by intradermal or subcutaneous injection. In another embodiment, the T cell composition of the present invention is preferably administered by intravenous injection. The composition of the T cell can be directly injected into the tumor, lymph node or infection site.

[0222] In certain embodiments of the invention, cells activated and expanded using the methods described herein or other methods known in the art to expand T cells to therapeutic levels are administered to patients in combination with any number of related treatment forms (e.g., before, simultaneously or after), including but not limited to treatment with the following agents: agents such as antiviral therapy, cidofovir and interleukin-2, cytarabine (also known as ARA-C) or natalizumab treatment for MS patients or efavirenz treatment for psoriasis patients or other treatments for PML patients. In further embodiments, the T cells of the present invention can be used in combination with chemotherapy, radiation, immunosuppressants such as cyclosporine, azathioprine, methotrexate, mycophenolate and FK506, antibodies or other immunotherapeutic agents. In further embodiments, the cell compositions of the present invention are administered to patients in combination with bone marrow transplantation, using chemotherapeutic agents such as fludarabine, external beam radiation therapy (XRT), cyclophosphamide (e.g., before, simultaneously or after). For example, in one embodiment, the subject can undergo standard treatment with high-dose chemotherapy followed by peripheral blood stem cell transplantation. In some embodiments, the subject receives an infusion of the expanded immune cells of the invention following transplantation. In an additional embodiment, the expanded cells are administered prior to or after surgery.

[0223] The dosage of the above treatments administered to a patient will vary with the precise nature of the condition being treated and the recipient of the treatment. The dosage ratio for human administration can be implemented according to practices accepted in the art. Typically, 1×10 5 to 1×10 10 The modified T cells of the present invention are administered to the patient, for example, by intravenous infusion.

[0224] Main advantages of the present invention

[0225] 1. The conditionally activated CAR and engineered immune cells of the present invention can effectively avoid off-target effects, thereby reducing toxic side effects and improving safety.

[0226] 2. When the conditionally activated CAR and engineered immune cells of the present invention exert their killing function, the extracellular conditionally activated regulatory elements have been cut off. Therefore, the presence of the conditionally activated regulatory elements of the present invention will not affect the killing function of the engineered immune cells themselves.

[0227] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0228] Sequence information

[0229]

[0230]

[0231]

[0232] Example 1 Construction of recombinant B7-H3.TSAR.CAR molecules and preparation of T cells expressing the CAR molecules

[0233] In this embodiment, taking esophageal malignancy and B7-H3 target as an example, a recombinant B7-H3.TSAR.CAR molecule (such as Figure 1 As shown) and preparing T cells expressing the CAR molecule, the steps are as follows:

[0234] ① Artificially synthesizing a CAR molecule containing a fusion gene of a TSAR regulatory element and a B7-H3 single-chain antibody (SEQ ID NO: 7);

[0235] ②Insert the artificially synthesized fusion gene into the lentiviral plasmid;

[0236] ③Use 293T cells to package and produce lentivirus to prepare lentivirus carrying B7-H3.TSAR.CAR molecules;

[0237] ④ Use Ficoll to separate mononuclear cells from peripheral blood, and further use CD3 magnetic beads to select and enrich T cells;

[0238] ⑤Use the lentivirus prepared in step ③ to infect human peripheral blood T cells to prepare recombinant B7-H3.TSAR.CAR-T cells, and amplify B7-H3.TSAR.CAR-T in vitro for subsequent in vitro and in vivo experiments.

[0239] like Figure 2 As shown, this is a schematic diagram of the TSAR.CAR-T cell anti-tumor effect of the present invention: Since the human body contains a large amount of human albumin, when TSAR.CAR-T enters the non-tumor area of ​​the human body, HSABP can immediately bind to HSA, causing the conformation of the extracellular structure of CAR-T cells to change. Due to the steric hindrance effect, scFv cannot smoothly bind to the B7-H3 protein, and B7-H3.TSAR.CAR-T is in an inactive state. When B7-H3.TSAR.CAR-T enters the tumor area, MMP1 expressed in large quantities in solid tumor tissues can cut B7-H3.TSAR.CAR-T at the MMPCS site, eliminating the steric hindrance effect, and B7-H3.TSAR.CAR-T becomes a classic activated B7-H3.CAR-T. The scFv binds to the tumor antigen binding region and the target antigen B7-H3 on the surface of the tumor cell to exert a tumor killing function.

[0240] Example 2 Detection of B7-H3 expression level on the surface of esophageal malignant tumor cell line using flow cytometry

[0241] In this example, taking esophageal malignant tumor and B7-H3 target as an example, flow cytometry was used to detect the expression level of B7-H3 on the surface of esophageal malignant tumor cell line, and the specific steps were as follows:

[0242] ① Use EDTA to digest the KYSE30 / 70 / 140 / 150 / 180 / 270 / 410 / 450 / 510 / 520 cell lines in the logarithmic growth phase;

[0243] ② Wash with PBS 3 times;

[0244] ③ Resuspend in 50 μl PBS, add PE-labeled B7-H3 (PE) antibody, and incubate at 4°C in the dark for 45 min;

[0245] ④ Wash with PBS 3 times;

[0246] ⑤Resuspend in 200 μl PBS and detect PE expression level by flow cytometry.

[0247] like Figure 3 As shown, B7-H3 was positively expressed in all esophageal squamous cell carcinoma cells.

[0248] Example 3 Detection of B7-H3 protein levels in esophageal malignant tumor cell lines using Western blot

[0249] In this example, taking esophageal malignant tumor and B7-H3 target as an example, Western blot was used to detect the B7-H3 protein level in esophageal malignant tumor cell lines. The specific steps are as follows:

[0250] ①Extract total protein from KYSE30 / 70 / 140 / 150 / 180 / 270 / 410 / 450 / 510 / 520 cell lines and quantify;

[0251] ② Take 10 μg of protein for sample loading;

[0252] ③Western blot (electrophoresis, membrane transfer, blocking, application of primary antibody, TBST washing, application of secondary antibody, TBST washing, exposure) was used to detect the expression of B7-H3 protein content.

[0253] like Figure 4 Western blot results showed that B7-H3 was positively expressed in all esophageal squamous cell carcinoma cells.

[0254] Example 4 Bioinformatics analysis of B7-H3 protein expression levels in different tissues

[0255] In this example, the Proteinatlas database (https: / / www.proteinatlas.org) was used to analyze the protein expression of B7-H3 in normal tissues.

[0256] like Figure 5 As shown, B7-H3 is positively expressed in various tissues, especially choroid plexus, adrenal gland, salivary gland, lung, stomach, gallbladder, pancreas, urinary bladder, prostate, endometrium, placenta, etc.

[0257] Example 5 Bioinformatics analysis of B7-H3 RNA expression levels in different tumor tissues

[0258] In this example, the GEPIA database (http: / / gepia2.cancer-pku.cn) was used to analyze the RNA expression of B7-H3 in different tumor tissues.

[0259] like Figure 6 As shown in the data, B7-H3 levels in COAD (colon cancer), DLBC (diffuse large B-cell lymphoma), ESCA (esophageal cancer), GBM (diffuse large B-cell lymphoma), HNSC (head and neck squamous cell carcinoma), KIRC (renal clear cell carcinoma), KIRP (renal papillary cell carcinoma), LGG (low-grade brain glioma), LUSC (lung squamous cell carcinoma), PAAD (pancreatic cancer), SKCM (skin melanoma), STAD (gastric adenocarcinoma), TCGT (testicular germ cell tumor), THYM (thymoma), and UCS (uterine carcinosarcoma) were significantly higher than those in adjacent cancer tissues.

[0260] Example 6 Bioinformatics Analysis of B7-H3 RNA Expression Levels in Different Tumor Tissues

[0261] In this example, the Proteinatlas database (https: / / www.proteinatlas.org) was used to analyze the protein expression of B7-H3 in different tumor tissues, and the antibody number was HPA00928 antibody.

[0262] like Figure 7 As shown, CD276 protein is expressed in glioma, thyroid cancer, lung cancer, colorectal cancer, head and neck tumors, gastric cancer, liver cancer, pancreatic cancer, bladder cancer, prostate cancer, testicular cancer, breast cancer, cervical cancer, endometrial cancer, ovarian cancer, melanoma, and skin cancer.

[0263] Example 7 RNA sequencing analysis of the RNA expression of MMPs in 120 pairs of esophageal squamous cell carcinoma tissues

[0264] This example involves the expression of MMPs family members in esophageal squamous cell carcinoma tissue, and the specific steps are as follows:

[0265] ① Collect 120 pairs of esophageal squamous cell carcinoma specimens (including tumor tissue and corresponding adjacent tissue);

[0266] ②Use RNA high-throughput sequencing to analyze the RNA expression profiles of 120 pairs (240) of clinical specimens;

[0267] ③The RNA expression of 17 MMPs (MMP1, MMP2, MMP3, MMP7, MMP9, MMP10, MMP11, MMP12, MMP13, MMP14, MMP15, MMP16, MMP17, MMP19, MMP23B, MMP25 and MMP28) was analyzed by bioinformatics, and relevant heat maps were drawn.

[0268] like Figure 8 As shown in the figure, except for MMP28, the expressions of other 16 MMPs members in tumors were higher than those in adjacent tissues.

[0269] Example 8 Expression of MMP1 and MMP11 in ten esophageal squamous cell carcinoma cell lines

[0270] This example involves verification of MMP1 protein expression in tumor cells, and the specific steps are as follows:

[0271] ① Extract and quantify proteins from 10 tumor cell lines;

[0272] ②Western blot (electrophoresis, membrane transfer, blocking, application of primary antibody, TBST washing, application of secondary antibody, TBST washing, exposure) was used to detect the expression of MMP1 protein content.

[0273] like Fig. 9As shown in the figure, ESCC cells not only express the full-length MMP1 (MMP1 OL) protein, but also express the active segment (22 / 25kD, MMP1AL) and inactive segment (27kD) proteins to varying degrees. The expression levels of MMP11 protein in ESCC cell lines vary, with relatively high levels in KYSE70, KYSE150, and KYSE510 cells, and relatively low levels in KYSE410 and KYSE520 cells.

[0274] Example 9 Construction of MMP1 overexpressing cells and protein expression verification

[0275] This example involves the construction of MMP1 overexpressing cells and protein expression verification, and the specific steps are as follows:

[0276] ① PCR was used to obtain the full length and active segment of MMP1 (98-276AA), and a recombinant lentiviral plasmid expressing MMP1 was constructed;

[0277] ②Use 293T cells to package and produce lentivirus containing the full-length and active segments of MMP1;

[0278] ③Use lentivirus containing full-length MMP1 and MMP1 active segment to infect KYSE150 cells, and construct KYSE150 cell lines overexpressing full-length MMP1 (KYSE150-hMMP1) and MMP1 active segment (KYSE150-hMMP1 activated length);

[0279] ④Extract the total protein of KYSE150 / KYSE150-hMMP1 / KYSE150-hMMP1 activated length cell lines and quantify;

[0280] ⑤Western blot (electrophoresis, membrane transfer, blocking, application of primary antibody, TBST washing, application of secondary antibody, TBST washing, exposure) was used to detect the expression of MMP1 protein content.

[0281] like Fig.10 As shown, Western blot results showed that the expression level of MMP1 in KYSE150 cells overexpressing full-length MMP1 and overexpressing active fragment of MMP1 was significantly increased compared with that in non-transduced KYSE150 cells.

[0282] Example 10 Flow cytometric analysis of B7-H3.TSAR.CAR-T's ability to effectively bind to HSA via HSABP

[0283] In this embodiment, flow cytometry analysis is performed to analyze the effective binding of B7-H3.TSAR.CAR-T to HSA through HSABP. The specific steps are as follows:

[0284] ①Take 1 mg of human albumin and use FITC-NHS activated ester for protein labeling. After terminating the reaction, use dialysis to remove excess fluorescent dye;

[0285] ②T, B7-H3.CAR-T, and B7-H3.TSAR.CAR-T were starved for 24 h (cultured in X-VIVO medium without human serum albumin and IL-2 at 37°C for 24 h);

[0286] ③ The starved cells were incubated with HSA-FITC at room temperature or 4°C for 10 min, 20 min, and 30 min respectively;

[0287] ④After washing with PBS three times, the FITC positive rate was measured by flow cytometry.

[0288] like Fig.11 As shown, the FITC positivity rate of B7-H3.TSAR.CAR-T was significantly higher than that of control T cells and B7-H3.CAR-T cells without regulatory elements, indicating that recombinant B7-H3.TSAR.CAR can effectively bind to HSA.

[0289] Example 11 Flow cytometric analysis of whether T cells expressing B7-H3.TSAR.CAR molecules can be activated by MMP1

[0290] In this embodiment, flow cytometry analysis is performed to determine whether T cells expressing B7-H3.TSAR.CAR molecules can be activated by MMP1. The specific steps are as follows:

[0291] ①Construct HSABP-MMPCS-scFv plasmid;

[0292] ② Induced expression of HSABP-MMPCS-scFv protein in vitro;

[0293] ③ Label the HSABP-MMPCS-scFv protein with FITC-NHS activated ester to obtain HSABP-MMPCS-scFv-FITC protein;

[0294] ④ EDTA digestion of KYSE150 cells;

[0295] ⑤ Some of the cells after incubation were incubated with HSABP-MMPCS-scFv-FITC at 37℃ for 1 hour, and the other part of the cells were incubated with activated MMP1 protein (activated by APMA at 37℃ for 2 hours) and HSABP-MMPCS-scFv-FITC at 37℃ for 1 hour;

[0296] ⑥ Detection of FITC expression by flow cytometry.

[0297] like Fig.12As shown, the cell group containing activated MMP1 protein was able to better bind to the fluorescently labeled HSABP-MMPCS-scFv recombinant protein, proving that MMP1 cleavage can relieve the blocking effect of HSA on single-chain antibody.

[0298] Example 12 In vitro analysis of B7-H3.TSAR.CAR-T and B7-H3.CAR-T against KYSE150 and KYSE150-hMMP1 activated length killing ability

[0299] The killing ability of CAR-T cells was detected by cell LDH release experiment for 24 hours. The inventors found that B7-H3.CAR-T cells had a significantly higher killing effect on KYSE150 cells with low MMP1 expression than B7-H3.TSAR.CAR-T cells. When co-incubated with KYSE150-hMMP1 cells overexpressing MMP1, B7-H3.TSAR.CAR-T and B7-H3.CAR-T had the same killing effect (e.g. Fig.13 As shown), it proves that MMP1 can activate B7-H3.TSAR.CAR-T cells and exert anti-tumor activity.

[0300] The above results show that the killing function of B7-H3.TSAR.CAR-T on tumor cells can be conditionally activated by MMP1, which improves safety: in cells with low expression of MMP1, B7-H3.TSAR.CAR-T is in a low activation state; while in cells with high expression of MMP1, B7-H3.TSAR.CAR-T is effectively activated. In addition, the results also show that TSAR regulatory elements do not affect the killing effect of B7-H3.TSAR.CAR-T on tumor cells.

[0301] Example 13 In vivo animal experiment comparing the killing ability of B7-H3.TSAR.CAR-T and B7-H3.CAR-T

[0302] In this embodiment, an in vivo animal experiment is performed to compare the killing ability of B7-H3.TSAR.CAR-T and B7-H3.CAR-T, and the specific steps are as follows:

[0303] ① Take 4-6 week old B-NDG mice and inoculate 4×10 KYSE70 cells subcutaneously. 6 / Only.

[0304] ②When the subcutaneous tumor volume increases to 100mm 3 At the time of treatment, the animals were divided into PBS group, T group, B7-H3.CAR-T group, and B7-H3.TSAR.CAR-T group (n=6 in each group), and the group treatment was performed twice;

[0305] ③The body weight and tumor volume of B-NDG mice were measured twice a week, and the changes in tumor volume among different treatment groups were compared.

[0306] like Fig.14As shown in the figure, the results showed that when B7-H3.TSAR.CAR-T and B7-H3.CAR-T were used to treat the MMP1 high-expressing cell line KYSE-70, tumor growth could be effectively inhibited, and there was no significant difference in the anti-tumor activity between the two. Therefore, the TSAR regulatory element does not affect the killing effect of B7-H3.TSAR.CAR-T on tumor cells.

[0307] Example 14 In vitro analysis of the anti-tumor activity of B7-H3.TSAR.CAR-T against various tumor cells

[0308] In this example, the anti-tumor activity of B7-H3.TSAR.CAR T cells was determined by luciferase method, and the specific steps are as follows:

[0309] ①Resuscitation and inoculation of colorectal cancer Colo205 cells, liver cancer HuH7 cells, gastric cancer SGC7901 cells, pancreatic cancer Panc1 cells, lung cancer NCI-H460 cells, melanoma A375 cells, and ovarian cancer SKOV3 cells into 12-well plates;

[0310] ② Add 50 μL of lentivirus expressing GFP and Luciferase (titer is 3*10 7 ), 5 μg Polybrene infection enhancer, fresh cell culture medium was replaced after 12 h of virus infection, and culture was continued for 72 h;

[0311] ③ 72 hours after infection, add blasticidin at a final concentration of 10 μg / mL for resistance screening for 3-5 days;

[0312] 5000-10000 cells were inoculated with control T (ConT) and B7-H3.TSAR.CAR-T with different effector-target ratios in an opaque sterile culture plate and incubated in a 37°C incubator for 24 h;

[0313] ④ Add 20 μL (1 μg / μL) of luciferase substrate;

[0314] ⑤ Analyze the luciferase activity of the remaining cells using the Promega GloMax assay;

[0315] ⑥Statistical analysis of the anti-tumor activity of T cells.

[0316] like Fig.15 As shown in the figure, the anti-tumor activity of B7-H3.TSAR.CAR-T against colorectal cancer Colo205 cells, liver cancer HuH7 cells, gastric cancer SGC7901 cells, pancreatic cancer Panc1 cells, lung cancer NCI-H460 cells, melanoma A375 cells, and ovarian cancer SKOV3 cells was significantly higher than that of control cells, and with the increase of the effector-target ratio, the anti-tumor activity of B7-H3.TSAR.CAR-T gradually increased.

[0317] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A conditionally activated chimeric antigen receptor (CAR), characterized in that: The conditionally activated chimeric antigen receptor comprises: (i) an extracellular domain comprising a TSAR regulatory element and an antigen recognition domain; (ii) a transmembrane domain linked to the extracellular domain; and (iii) an intracellular domain linked to the transmembrane domain; in: The TSAR regulatory elements include: serum albumin binding peptide and matrix metalloproteinase cleavage sequence; The antigen recognition domain targets tumor antigens.

2. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the conditionally activated chimeric antigen receptor according to claim 1.

3. A carrier, characterized in that The vector contains the nucleic acid molecule according to claim 2.

4. A host cell, characterized in that The host cell contains the vector according to claim 3, or has the exogenous nucleic acid molecule according to claim 2 integrated into its chromosome, or expresses the conditionally activated chimeric antigen receptor according to claim 1.

5. An engineered immune cell, characterized in that: The engineered immune cell contains the vector as described in claim 3, or an exogenous nucleic acid molecule as described in claim 2 is integrated into its chromosome, or it expresses the conditionally activated chimeric antigen receptor as described in claim 1, and the engineered immune cell is a T cell, NK cell, NKT cell, or macrophage.

6. A method for preparing the engineered immune cell according to claim 5, characterized in that: The method comprises the following steps: transducing the nucleic acid molecule according to claim 2 or the vector according to claim 3 into immune cells, thereby obtaining the engineered immune cells.

7. A pharmaceutical composition, characterized in that The pharmaceutical composition contains: (Z1) the conditionally activated chimeric antigen receptor of claim 1, the nucleic acid molecule of claim 2, the vector of claim 3, the host cell of claim 4, the engineered immune cell of claim 5, or a combination thereof; and (Z2) a pharmaceutically acceptable carrier, diluent or excipient.

8. A use of the conditionally activated chimeric antigen receptor according to claim 1, the nucleic acid molecule according to claim 2, the vector according to claim 3, the host cell according to claim 4, and / or the engineered immune cell according to claim 5, characterized in that: Used for preparing medicines or preparations for preventing and / or treating cancer or tumors.

9. A method for modifying a chimeric antigen receptor (CAR), characterized in that: The method comprises the steps of: (a) providing a chimeric antigen receptor to be engineered; and (b) Introducing a TSAR regulatory element in front of the antigen recognition domain of the chimeric antigen receptor to be modified, thereby obtaining a conditionally activated chimeric antigen receptor with higher safety.

10. A kit for preparing the engineered immune cell according to claim 5, the kit comprising a container, and the nucleic acid molecule according to claim 2 or the vector according to claim 3 located in the container.

Citation Information

Patent Citations

  • Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof

    US5350674A

  • Gene therapy

    US5399346A

  • Delivery of exogenous DNA sequences in a mammal

    US5580859A

  • Adenovirus vectors for gene therapy

    US5585362A

  • Induction of a protective immune response in a mammal by injecting a DNA sequence

    US5589466A